On Monday, Sarepta Therapeutics Inc. SRPT launched topline outcomes from Half 2 of EMBARK (Research SRP-9001-301) Section 3 medical examine of Elevidys (delandistrogene moxeparvovec-rokl), the one accredited gene remedy in sufferers with Duchenne muscular dystrophy.
Crossover-treated sufferers who obtained a placebo in Half 1, crossed over at 52 weeks and had been handled with Elevidys in Half 2 improved 2.34 factors from baseline in comparison with matched exterior controls on the North Star Ambulatory Evaluation (NSAA) 52 weeks after therapy. NSAA measures purposeful motor talents in youngsters with Duchenne.
Additionally Learn: Strong Biosciences Outpaces Rivals In Duchenne Gene Remedy Growth
Regardless of being one yr older (common age 7.18 years) than these handled in Half 1 (common age 5.98 years), crossover-treated sufferers confirmed clinically significant and statistically vital purposeful profit for NSAA, Time to Rise (TTR) and 10-meter stroll/run (10MWR) operate assessments in contrast with a pre-specified, propensity-weighted exterior management group (EC).
People handled partially one in every of EMBARK (n=63) confirmed clinically significant and statistically vital enhancements on the NSAA sustained two years after therapy with Elevidys. Purposeful motor enhancements embrace:
- +2.88 factors (enchancment) on NSAA.
- -2.06 seconds (enchancment) on Time to Rise.
- -1.36 seconds (enchancment) on 10MWR.
Muscle biopsies from a subset of sufferers taken 64 weeks after dosing partially one confirmed constant and sustained expression of micro-dystrophin. Muscle pathology on MRI continues to point out minimal development in underlying muscle pathology and stays extremely in step with the purposeful advantages proven.
No new security alerts had been noticed.
As a part of a collaboration settlement signed in 2019, Sarepta is working with Roche Holdings AG RHHBY. Sarepta is accountable for regulatory approval and commercializing Elevidys within the U.S. and manufacturing.
Roche is accountable for regulatory approvals and bringing Elevidys to sufferers throughout the remainder of the world.
Value Motion: SRPT inventory closed at $116.46 on Friday.
Learn Subsequent:
Overview Score:
Speculative
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
